Natixis Advisors LLC Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Natixis Advisors raised its stake in Edwards Lifesciences by 8.7% to 257,302 shares (about $20.01M); overall institutional ownership is ~79.5% with Vanguard, BNY Mellon, Jennison and DZ BANK among others also increasing positions.
• Significant insider selling has occurred recently — VP Donald Bobo Jr. sold 24,000 shares (~53% reduction) and CFO Scott Ullem sold 13,000 shares (~24.7% reduction); insiders have sold 74,123 shares (≈$6.28M) in the last 90 days, which could pressure sentiment.
• Shares trade in the mid‑$80s (50/200‑day MAs ≈ $82.5/$81.6) with a market cap of ≈ $49.4B and a P/E of ~46.5; the company missed EPS ($0.58 vs $0.62) while revenue rose 13.3% to $1.57B, and analysts' consensus is a "Moderate Buy" with a ~$96.14 target.

Natixis Advisors LLC raised its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 8.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 257,302 shares of the medical research company's stock after buying an additional 20,574 shares during the period. Natixis Advisors LLC's holdings in Edwards Lifesciences were worth $20,010,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Geode Capital Management LLC boosted its position in Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company's stock worth $990,074,000 after purchasing an additional 45,555 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Brokerage consensus remains constructive — Edwards has an average rating of "Moderate Buy," which supports longer-term investor demand and suggests analysts see upside vs. current valuation. Article Title
• Positive Sentiment: Equity research and trade ideas continue to include EW among attractive medical-instruments names, citing product pipeline, secular TAVR/TMV growth and margin upside — a positive for investor interest and potential inflows. Article Title
• Neutral Sentiment: Management presented at recent healthcare conferences (Barclays and Leerink); transcripts are available for investors to assess guidance, R&D and commercial cadence but contained no market-moving surprises in summary. These presentations can influence sentiment depending on Q&A details. Barclays Transcript Leerink Transcript
• Negative Sentiment: Significant insider selling by senior finance staff: CFO Scott Ullem sold 13,000 shares (a ~24.7% reduction in his holding) at ~$84.92 — a sizeable, public reduction by the company’s finance chief can alarm investors about near-term conviction. SEC Filing
• Negative Sentiment: Additional insider sale: VP Daniel Lippis sold 1,019 shares at ~$85.38. Though smaller, combined insider selling activity increases pressure on sentiment. SEC Filing
• Negative Sentiment: Short interest jumped sharply in February (up ~56.6% to ~12.38M shares, ~2.1% of shares outstanding), suggesting increased bearish bets that can amplify downward moves and volatility on negative headlines. (No link provided)

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Evercore restated an "outperform" rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, January 12th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research report on Wednesday, December 17th. Finally, Citigroup reaffirmed a "buy" rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,371,239.08. The trade was a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 74,123 shares of company stock valued at $6,275,599 over the last ninety days. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $85.08 on Thursday. The business has a 50-day moving average of $82.49 and a two-hundred day moving average of $81.55. The firm has a market capitalization of $49.42 billion, a PE ratio of 46.49, a P/E/G ratio of 2.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. The business's revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.